Age, Gender, and Race Analyses of D/C/F/TAF in HIV-1 Treatment-naïve Patients

Bruce Rashbaum,¹ Cheryl McDonald,² Cristina Mussini,³ Christoph D. Spinner,⁴ John Jezorwski,⁵ Eric Y. Wong,⁶ Kimberley Brown⁶

¹CapMed/Medical Associates, Washington, DC, USA; ²Tarrant County Infectious Disease Associates, Fort Worth, TX, USA; ³University of Modena and Reggio Emilia, Modena, Italy; ⁴Technische Universität München, Munich, Germany; ⁵Janssen Research & Development, LLC, Pennington, NJ, USA; ⁶Janssen Scientific Affairs, LLC, Titusville, NJ, USA.

INTRODUCTION

OBJECTIVE

METHODS

Study Design

Analyses

RESULTS

Patient Population

PRELIMINARY DATA

Efficacy

Safety

Patient characteristics

Age subgroups

Gender subgroups

Race subgroups

CONCLUSIONS

DISCLOSURES

ACKNOWLEDGMENTS

REFERENCES

POSTER PRESENTED AT THE CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI); MARCH 4-7, 2018; BOSTON, MASSACHUSETTS.